The estimated Net Worth of Mats Wahlstrom is at least $12.2 Миллион dollars as of 1 February 2024. Mr. Wahlstrom owns over 59,988 units of Coherus Biosciences Inc stock worth over $132,984 and over the last 10 years he sold CHRS stock worth over $11,756,626. In addition, he makes $261,402 as Lead Independent Director at Coherus Biosciences Inc.
Mats has made over 7 trades of the Coherus Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 59,988 units of CHRS stock worth $100,180 on 1 February 2024.
The largest trade he's ever made was selling 200,000 units of Coherus Biosciences Inc stock on 17 June 2020 worth over $3,430,000. On average, Mats trades about 23,441 units every 129 days since 2014. As of 1 February 2024 he still owns at least 99,988 units of Coherus Biosciences Inc stock.
You can see the complete history of Mr. Wahlstrom stock trades at the bottom of the page.
Mats Wahlstrom serves as Lead Independent Director of the Company. He has served as a member of our Board of Directors since January 2012. He currently serves as the Executive Chairman of KMG Capital Partners, LLC, where he has been a senior leader since April 2012, Chairman of Triomed AB since October 2016, Chairman of Surefire Medical, Inc. (DBA TriSalus Life Sciences) since January 2017 and Chairman of Caduceus Medical Holdings, Inc. since August 2010. He has served on the boards of directors of Alteco Medical AB since October 2012, Empirican Group, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc., a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, a director of Getinge AB, a Swedish stock exchange-listed medical device company, from March 2012 to March 2017 and as a director of Zynex Inc., an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group. Mr. Wahlström has a B.S. degree in Economics and Business Administration from University of Lund, Sweden.
As the Lead Independent Director of Coherus Biosciences Inc, the total compensation of Mats Wahlstrom at Coherus Biosciences Inc is $261,402. There are 6 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.
Mats Wahlstrom is 66, he's been the Lead Independent Director of Coherus Biosciences Inc since 2012. There are 3 older and 11 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
Mats's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle и James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: